Article

The costs and effectiveness of four HIV counseling and testing strategies in Uganda

US Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Atlanta, Georgia, USA.
AIDS (London, England) (Impact Factor: 6.56). 01/2009; 23(3):395-401. DOI: 10.1097/QAD.0b013e328321e40b
Source: PubMed

ABSTRACT HIV counseling and testing (HCT) is a key intervention for HIV/AIDS control, and new strategies have been developed for expanding coverage in developing countries. We compared costs and outcomes of four HCT strategies in Uganda.
A retrospective cohort of 84 323 individuals received HCT at one of four Ugandan HCT programs between June 2003 and September 2005. HCT strategies assessed were stand-alone HCT; hospital-based HCT; household-member HCT; and door-to-door HCT.
We collected data on client volume, demographics, prior testing and HIV diagnosis from project monitoring systems, and cost data from project accounts and personnel interviews. Strategies were compared in terms of costs and effectiveness at reaching key population groups.
Household-member and door-to-door HCT strategies reached the largest proportion of previously untested individuals (>90% of all clients). Hospital-based HCT diagnosed the greatest proportion of HIV-infected individuals (27% prevalence), followed by stand-alone HCT (19%). Household-member HCT identified the highest percentage of discordant couples; however, this was a small fraction of total clients (<4%). Costs per client (2007 USD) were $19.26 for stand-alone HCT, $11.68 for hospital-based HCT, $13.85 for household-member HCT, and $8.29 for door-to-door-HCT.
All testing strategies had relatively low per client costs. Hospital-based HCT most readily identified HIV-infected individuals eligible for treatment, whereas home-based strategies more efficiently reached populations with low rates of prior testing and HIV-infected people with higher CD4 cell counts. Multiple HCT strategies with different costs and efficiencies can be used to meet the UNAIDS/WHO call for universal HCT access by 2010.

Full-text

Available from: Rhoda K Wanyenze, Jun 14, 2015
3 Followers
 · 
332 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Efforts to increase awareness of HIV status have led to growing interest in community-based models of HIV testing. Maximizing the benefits of such programmes requires timely linkage to care and treatment. Thus, an understanding of linkage and its potential barriers is imperative for scale-up. This study was conducted in rural South Africa. HIV-positive clients (n=492) identified through home-based HIV counselling and testing (HBHCT) were followed up to assess linkage to care, defined as obtaining a CD4 count. Among 359 eligible clients, we calculated the proportion that linked to care within three months. For 226 clients with available data, we calculated the median CD4. To determine factors associated with the rate of linkage, Cox regression was performed on a subsample of 196 clients with additional data on socio-demographic factors and personal characteristics. We found that 62.1% (95% CI: 55.7 to 68.5%) of clients from the primary sample (n=359) linked to care within three months of HBHCT. Among those who linked, the median CD4 count was 341 cells/mm(3) (interquartile range [IQR] 224 to 542 cells/mm(3)). In the subsample of 196 clients, factors predictive of increased linkage included the following: believing that drugs/supplies were available at the health facility (adjusted hazard ratio [aHR] 1.78; 95% CI: 1.07 to 2.96); experiencing three or more depression symptoms (aHR 2.09; 95% CI: 1.24 to 3.53); being a caregiver for four or more people (aHR 1.93; 95% CI: 1.07 to 3.47); and knowing someone who died of HIV/AIDS (aHR 1.68; 95% CI: 1.13 to 2.49). Factors predictive of decreased linkage included the following: younger age - 15 to 24 years (aHR 0.50; 95% CI: 0.28 to 0.91); living with two or more adults (aHR 0.52; 95% CI: 0.35 to 0.77); not believing or being unsure about the test results (aHR 0.48; 95% CI: 0.30 to 0.77); difficulty finding time to seek health care (aHR 0.40; 95% CI: 0.24 to 0.67); believing that antiretroviral treatment can make you sick (aHR 0.56; 95% CI: 0.35 to 0.89); and drinking alcohol (aHR 0.52; 95% CI: 0.34 to 0.80). The findings highlight barriers to linkage following an increasingly popular model of HIV testing. Further, they draw attention to ways in which practical interventions and health education strategies could be used to improve linkage to care.
    Journal of the International AIDS Society 06/2015; 18. DOI:10.7448/IAS.18.1.19843 · 4.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is limited research characterizing the HIV care continuum with population-based data in sub-Saharan Africa. The objectives of this study were to: 1) describe engagement in care among all known HIV-positive adults in one sub-county of western Kenya; and 2) determine the time to and predictors of linkage and engagement among adults newly diagnosed via home-based counseling and testing (HBCT). AMPATH (Academic Model Providing Access to Healthcare) has provided HIV care in western Kenya since 2001 and HBCT since 2007. Following a widespread HBCT program in Bunyala sub-county, electronic medical records (EMR) were reviewed to identify uptake of care among individuals with previously known (self-reported) infection and new (identified by HBCT) HIV diagnoses as of June 2014. Engagement in HIV care was defined as an initial encounter with an HIV care provider. Cox regression analysis was used to examine the predictors of engagement among those newly diagnosed. Of the 3,482 infected adults identified, 61% had previously known infections, among whom 84% (n = 1778/2122) had ever had at least one clinical encounter within AMPATH. While 73% were registered in the EMR, only 15% (n = 209/1360) of the newly diagnosed had seen a clinician over a median of 3·4 years. The median time to engagement among the newly diagnosed was 60 days (interquartile range: 10-411 days). Engagement in care was high among those who at the time of HBCT were already known HIV-positive, but few who were newly diagnosed in HBCT saw an HIV care provider. This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through USAID under the terms of Cooperative Agreement No. AID-623-A-12-0001. The HBCT program was supported by grants from Abbott Laboratories, the Purple ville Foundation, and the Global Business Coalition. Abbott Laboratories provided test kits and logistical support. Further support was provided by the National Institute of Mental Health (K01MH099966, PI: Genberg) and the Bill and Melinda Gates Foundation. The contents of this study are the sole responsibility of the authors and do not necessarily reflect the views of USAID, NIMH, BMGF, or the United States Government.
    The Lancet HIV 01/2015; 2(1):e20-e26. DOI:10.1016/S2352-3018(14)00034-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Home HIV counselling and testing (HTC) has been shown to achieve high testing coverage and linkage to care compared to existing facility-based HTC, particularly among asymptomatic persons. This study evaluates the population-level health impact and cost-effectiveness of a community-based home HTC package in KwaZulu-Natal, South Africa. We parameterized an individual-based model with data from home HTC and linkage field studies that achieved high coverage (91%) and linkage to ART (80%) in rural KwaZulu-Natal, South Africa. Costs were derived from a linked micro-costing study. The model simulated 10,000 individuals over ten years and incremental cost-effectiveness ratios (ICERs) were calculated for the intervention relative to the existing 'status quo' of facility-based testing, with costs discounted at 3% annually. Implementing home HTC in addition to current practice is predicted by the model to decrease HIV-associated morbidity by 10-22% and HIV infections by 9-47% with increasing CD4 threshold for ART initiation. Incremental programme costs were US$2.7-4.4 million higher in the intervention scenarios compared to baseline with higher costs associated with increasing ART initiation criteria; ART accounted for 48-87% of total costs. Across all ART initiation thresholds, ICERs were US$1,340, $1,090, $1,150 and $1,360 per DALY averted at ≤200, ≤350, ≤500 cells/mm(3) and universal ART access, respectively. Increases in HIV testing and linkage to care following community-based HTC propagate into population-level health outcomes. The ICERS are <20% of GDP per capita in South Africa and therefore considered very cost-effective. Home HTC should be considered a viable means by which programs can achieve ambitious new targets for HIV treatment.
    The Lancet HIV 04/2015; 2(4):e159-e168. DOI:10.1016/S2352-3018(15)00016-8